Drug Price Trends for INSULIN GLARGINE-YFGN U100 VL

Average Pharmacy Cost for INSULIN GLARGINE-YFGN U100 VL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
INSULIN GLARGINE-YFGN U100 VL	49502-0393-80	6.07969	ML	2024-12-18
INSULIN GLARGINE-YFGN U100 VL	83257-0014-11	6.07969	ML	2024-12-18
INSULIN GLARGINE-YFGN U100 VL	49502-0393-80	6.07545	ML	2024-11-20
INSULIN GLARGINE-YFGN U100 VL	83257-0014-11	6.07545	ML	2024-11-20
INSULIN GLARGINE-YFGN U100 VL	83257-0014-11	6.09209	ML	2024-10-23
INSULIN GLARGINE-YFGN U100 VL	49502-0393-80	6.09209	ML	2024-10-23

Market Analysis and Price Projections for Insulin Glargine-YFGN U100

Market Overview

The global insulin glargine market, which includes products like Insulin Glargine-YFGN U100, is experiencing significant growth driven by increasing diabetes prevalence and advancements in insulin delivery technologies.

• Global Market Size: The market was valued at USD 1.29 billion in 2022 and is projected to reach USD 2.2 billion by 2031, growing at a CAGR of 6.11% during the forecast period (2023-2031)[1][3].
• Regional Dominance: North America holds the largest market share due to a high-quality healthcare system and the increasing prevalence of diabetes in the region[3][4].

Market Drivers

Several factors are driving the growth of the insulin glargine market:

• Increasing Diabetes Prevalence: The global rise in diabetes cases, particularly Type 1 and Type 2 diabetes, is a major driver. Sedentary lifestyles and other health factors contribute to this increase[3][4].
• Advancements in Technology: Improvements in insulin delivery devices and the launch of new products by key players are expanding market opportunities[3][4].
• Health Awareness and Policies: Increasing health awareness and supportive remuneration policies also contribute to the market's growth[3].

Key Players

The insulin glargine market is moderately consolidated, with a few major players dominating the landscape:

• Sanofi: Known for its brand Lantus and the recently introduced unbranded biologic at a lower price point[5].
• Novo Nordisk: A significant player with a global presence.
• Eli Lilly and Company: Collaborates with Boehringer Ingelheim on Basaglar, a biosimilar to Lantus[4].
• Biocon: Partners with Mylan to develop Semglee, another insulin glargine biosimilar[4].

Price Trends and Projections

Current Pricing

• The cost for insulin glargine (yfgn 100 units/mL) can vary, but it is generally around $75 to $129 for a 10 milliliter supply, depending on the pharmacy and any discounts or programs applied[2].
• For example, the price for Insulin Glargine-YFGN U100 PEN was around $5.93 per milliliter as of late 2024[1].

Price Reduction Initiatives

• Sanofi has made significant price reductions, cutting the list price of Lantus by 78% and capping out-of-pocket costs at $35 for patients with commercial insurance, effective January 1, 2024[5].
• Similar initiatives include the Insulins Valyou Savings Program, which allows uninsured patients to purchase insulin at $35 for a 30-day supply[5].

Future Projections

• The market is expected to grow at a CAGR of 6.11% to 6.28% during the forecast periods of 2023-2031 and 2024-2029, respectively[1][3][4].
• This growth will be driven by increasing demand due to the rising prevalence of diabetes and the expansion of access to affordable insulin through various savings programs and price reductions.

Market Access and Affordability

Savings Programs

• Sanofi’s copay assistance programs limit out-of-pocket expenses for commercially insured patients to $15 or less for a 30-day supply of diabetes medicines[5].
• The Insulins Valyou Savings Program allows uninsured patients to buy insulin at $35 for a 30-day supply[5].

Regulatory and Policy Impact

• Regulatory approvals and expansions, such as the European Commission’s approval of Toujeo for children and adolescents, are also driving market growth[4].
• Broader systemic changes are needed to ensure that price reductions translate into savings for patients at the pharmacy counter[5].

Challenges and Restraints

• High Product Costs: Despite price reductions, the higher cost of insulin products remains a significant challenge, particularly in regions with strict regulatory environments[3].
• Substitutes and Competition: The availability of substitutes and biosimilars, along with regulatory hurdles, can restrain market growth[3].

Industry Overview

The insulin glargine market is characterized by:

• Moderate Consolidation: The market is dominated by a few major players who have established strong supply chains and branding, resulting in substantial market penetration[4].
• Mergers and Acquisitions: Recent alliances and collaborations among key players have strengthened their market positions[4].

Key Takeaways

• The global insulin glargine market is growing rapidly due to increasing diabetes prevalence and technological advancements.
• Major players like Sanofi, Novo Nordisk, and Eli Lilly are driving market growth through new product launches and price reduction initiatives.
• Savings programs and regulatory approvals are expanding market access and affordability.
• Despite growth, the market faces challenges such as high product costs and regulatory hurdles.

FAQs

1. What is the current size of the global insulin glargine market? The global insulin glargine market was valued at USD 1.29 billion in 2022[1][3].

2. What is the projected growth rate of the insulin glargine market? The market is expected to grow at a CAGR of 6.11% to 6.28% during the forecast periods of 2023-2031 and 2024-2029, respectively[1][3][4].

3. Who are the major players in the insulin glargine market? The major players include Sanofi, Novo Nordisk, Eli Lilly and Company, Biocon, and Julphar[4].

4. What initiatives have been taken to reduce the cost of insulin glargine? Sanofi has cut the list price of Lantus by 78% and capped out-of-pocket costs at $35 for patients with commercial insurance. Other savings programs like the Insulins Valyou Savings Program also offer discounted prices for uninsured patients[5].

5. Which region has the largest market share in the insulin glargine market? North America holds the largest market share due to its high-quality healthcare system and the increasing prevalence of diabetes in the region[3][4].

Sources

1. Drug Patent Watch: "Drug prices and trends for INSULIN GLARGINE-YFGN U100 PEN"
2. Drugs.com: "Insulin glargine Prices, Coupons, Copay Cards & Patient Assistance"
3. Straits Research: "Insulin Glargine Market Size to Reach 2200 Million by 2031"
4. Mordor Intelligence: "Insulin Glargine Market - Size & Share"
5. Sanofi: "Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance"